Vaccinex, Inc.
Index- P/E- EPS (ttm)-0.79 Insider Own1.70% Shs Outstand38.76M Perf Week3.51%
Market Cap48.67M Forward P/E- EPS next Y- Insider Trans- Shs Float37.52M Perf Month-3.28%
Income-22.40M PEG- EPS next Q- Inst Own44.20% Short Float1.44% Perf Quarter-11.28%
Sales0.90M P/S54.08 EPS this Y49.50% Inst Trans76.20% Short Ratio4.39 Perf Half Y-26.71%
Book/sh0.42 P/B2.81 EPS next Y- ROA- Target Price- Perf Year-49.57%
Cash/sh0.41 P/C2.90 EPS next 5Y- ROE- 52W Range0.90 - 3.28 Perf YTD13.46%
Dividend- P/FCF- EPS past 5Y19.40% ROI-280.70% 52W High-64.02% Beta1.10
Dividend %- Quick Ratio10.00 Sales past 5Y23.30% Gross Margin- 52W Low31.11% ATR0.09
Employees39 Current Ratio10.00 Sales Q/Q- Oper. Margin- RSI (14)46.60 Volatility9.42% 8.72%
OptionableYes Debt/Eq0.02 EPS Q/Q- Profit Margin- Rel Volume0.40 Prev Close1.16
ShortableYes LT Debt/Eq0.01 Earnings- Payout- Avg Volume122.84K Price1.18
Recom1.00 SMA20-3.16% SMA50-7.73% SMA200-26.80% Volume49,127 Change1.72%
Sep-23-20Downgrade BTIG Research Buy → Neutral
Sep-04-18Initiated Ladenburg Thalmann Buy $22
May-25-22 08:00AM  
May-16-22 08:15AM  
Apr-25-22 08:00AM  
Mar-31-22 09:15AM  
Mar-09-22 09:00AM  
Feb-24-22 08:00AM  
Feb-11-22 11:24AM  
Jan-28-22 07:57AM  
Jan-27-22 04:15PM  
Jan-26-22 11:18AM  
Jan-04-22 08:00AM  
Nov-10-21 08:00AM  
Nov-09-21 08:00AM  
Nov-08-21 08:15AM  
Nov-04-21 08:00AM  
Nov-01-21 08:00AM  
Sep-17-21 08:00AM  
Sep-15-21 08:00AM  
Aug-16-21 08:15AM  
Jul-21-21 07:45AM  
Jun-30-21 08:00AM  
Jun-08-21 07:57AM  
May-19-21 08:00AM  
May-17-21 08:15AM  
Apr-21-21 08:00AM  
Mar-16-21 08:05AM  
Mar-11-21 08:00AM  
Feb-23-21 07:25AM  
Feb-22-21 08:30AM  
Feb-19-21 12:20PM  
Jan-07-21 08:19AM  
Jan-06-21 08:43AM  
Jan-05-21 08:00AM  
Nov-13-20 08:05AM  
Oct-29-20 11:15AM  
Oct-26-20 07:55AM  
Oct-12-20 08:53AM  
Sep-23-20 10:34AM  
Sep-22-20 08:40AM  
Sep-17-20 08:00AM  
Aug-27-20 08:00AM  
Aug-14-20 09:45AM  
Aug-05-20 12:30PM  
Jul-16-20 11:30AM  
Jul-07-20 08:37AM  
Jun-09-20 08:00AM  
May-14-20 10:05AM  
May-13-20 05:02PM  
Apr-27-20 07:45AM  
Apr-07-20 07:55AM  
Mar-31-20 07:55AM  
Mar-09-20 07:46AM  
Feb-06-20 07:31AM  
Dec-10-19 08:02AM  
Dec-09-19 07:55AM  
Nov-25-19 07:18PM  
Nov-14-19 07:55AM  
Nov-12-19 08:00AM  
Nov-09-19 08:02AM  
Oct-31-19 09:14AM  
Sep-27-19 06:05AM  
Sep-24-19 08:05AM  
Sep-06-19 10:45AM  
Aug-14-19 12:18PM  
Aug-13-19 08:05AM  
Aug-12-19 05:49PM  
Aug-02-19 01:41PM  
Aug-01-19 09:15AM  
Jul-31-19 07:30AM  
Jun-03-19 08:00AM  
May-15-19 08:10AM  
Apr-09-19 08:30AM  
Apr-01-19 08:00AM  
Mar-13-19 08:30AM  
Mar-06-19 08:30AM  
Jan-17-19 08:30AM  
Jan-16-19 08:30AM  
Dec-12-18 12:18PM  
Nov-27-18 07:30AM  
Nov-15-18 08:30AM  
Nov-13-18 07:58AM  
Nov-12-18 08:30AM  
Nov-06-18 08:30AM  
Oct-23-18 08:30AM  
Oct-02-18 08:30AM  
Sep-27-18 08:30AM  
Sep-25-18 08:30AM  
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs. The company offers its products for the treatment of cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab, a humanized monoclonal antibody that completed and planned Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), Huntington's disease, Alzheimer's disease, osteosarcoma, and melanoma. The company is also developing VX5, a human antibody to CXCL13 that is in preclinical development for the treatment of MS and for other autoimmune disorders. Vaccinex, Inc. was incorporated in 2001 and is headquartered in Rochester, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Van Strydonck, Gerald E.DirectorFeb 23Buy1.3220,00026,36020,000Feb 24 04:37 PM
Frieberg Jacob B.DirectorJan 27Buy1.1190,090100,00094,510Jan 31 04:26 PM
FRIEDBERG ALBERTDirectorJan 27Buy1.113,603,6023,999,99811,580,436Jan 31 04:24 PM
Zauderer MauricePresident and CEOJan 27Buy1.111,801,8011,999,9992,899,554Jan 31 04:23 PM